Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > July 8, 2022
Daily News
July 8, 2022
- As LOEs Loom, Can Mochida Roll Out Authorized Generics for Lexapro and Lialda?
July 8, 2022
- Shipment Restrictions Continue for Vyndaqel, Vynmac: Pfizer Japan
July 8, 2022
- Japan to Discuss Fourth COVID Shot for Below Age 60: Govt Official
July 8, 2022
- Panel Designates COVID, Monkeypox and Other Priority Infectious Diseases for SCARDA Funding
July 8, 2022
- Japan Ethical Drug Sales Surge 6.2% in May: Crecon
July 8, 2022
- Lilly Japan, Mitsubishi Tanabe Link Up to Copromote Diabetes Med Tirzepatide
July 8, 2022
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…